Francesco Giuseppe De Rosa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1599226/publications.pdf

Version: 2024-02-01

271 papers

8,860 citations

45 h-index 84 g-index

277 all docs

277 docs citations

times ranked

277

10355 citing authors

#	Article	IF	CITATIONS
1	Vaccine development and technology for SARSâ€CoVâ€2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	5.0	8
2	Impact of an empiric antimicrobial therapy manual on antimicrobial usage and multidrug resistant organism trends in a large Italian teaching hospital. Infection Prevention in Practice, 2022, 4, 100187.	1.3	3
3	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2022, 11, 635-638.	4.0	1
4	Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS). Antibiotics, 2022, 11, 56.	3.7	2
5	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. JAC-Antimicrobial Resistance, 2022, 4, dlac022.	2.1	17
6	Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia. Biomedicines, 2022, 10, 820.	3.2	8
7	Bacterial and Viral Infection and Sepsis in Kidney Transplanted Patients. Biomedicines, 2022, 10, 701.	3.2	9
8	Disseminated Cryptococcosis Complicating Severe SARS-CoV-2 Infection. BioMed, 2022, 2, 127-132.	1.1	2
9	Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. Clinical Microbiology and Infection, 2022, 28, 1290.e1-1290.e4.	6.0	7
10	Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group. Infezioni in Medicina, 2022, 30, 80-85.	1.1	1
11	Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic. Antibiotics, 2022, 11, 493.	3.7	8
12	Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocolâ€"An All-Inclusive Guide for Clinicians. Pharmaceuticals, 2022, 15, 463.	3.8	13
13	Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence. Infection and Drug Resistance, 2022, Volume 15, 2137-2157.	2.7	7
14	Effectiveness of an Active and Continuous Surveillance Program for Intensive Care Units Infections Based on the EPIC III (Extended Prevalence of Infection in Intensive Care) Approach. Journal of Clinical Medicine, 2022, 11, 2482.	2.4	2
15	Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey. Anaerobe, 2022, 75, 102583.	2.1	13
16	An Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs. Antibiotics, 2022, 11, 695.	3.7	19
17	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. Pharmaceuticals, 2022, 15, 630.	3.8	0
18	Bloodstream Infections Caused by Carbapenem-Resistant Pathogens in Intensive Care Units: Risk Factors Analysis and Proposal of a Prognostic Score. Pathogens, 2022, 11, 718.	2.8	11

#	Article	IF	Citations
19	Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives. Biomedicines, 2022, 10, 1561.	3.2	3
20	Infective Endocarditis in People Who Inject Drugs: Report from the Italian Registry of Infective Endocarditis. Journal of Clinical Medicine, 2022, 11, 4082.	2.4	4
21	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. Journal of Chemotherapy, 2021, 33, 435-439.	1.5	2
22	Epidemiology, prevalence and risk factors for infections in burn patients: results from a regional burn centre's analysis. Journal of Chemotherapy, 2021, 33, 62-66.	1.5	11
23	Detection of Carbapenemase and CTX-M Encoding Genes Directly from Bronchoalveolar Lavage Using the CRE and ESBL ELITe MGB Assays: Toward Early and Optimal Antibiotic Therapy Management of Critically III Patients with Pneumonia. Microbial Drug Resistance, 2021, 27, 241-246.	2.0	1
24	Giardiasis reactivation during severe SARS-CoV-2 infection. Parasitology International, 2021, 80, 102241.	1.3	8
25	Ozone therapy in COVID-19: A narrative review. Virus Research, 2021, 291, 198207.	2.2	44
26	Ceftobiprole Perspective: Current and Potential Future Indications. Antibiotics, 2021, 10, 170.	3.7	17
27	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
28	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically III Patients with COVID-19: A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 555.	2.4	93
29	Personalized stewardship and interdisciplinarity: key elements of COVID-19. Microbes and Infection, 2021, 23, 104781.	1.9	0
30	Cost-Effectiveness Analysis of the Prophylactic Use of Ertapenem for the Prevention of Surgical Site Infections after Elective Colorectal Surgery. Antibiotics, 2021, 10, 259.	3.7	0
31	COVID-19 pneumonia: do notÂleave the corticosteroids behind!. Future Microbiology, 2021, 16, 317-322.	2.0	7
32	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Review of Anti-Infective Therapy, 2021, 19, 1125-1134.	4.4	11
33	Putative invasive pulmonary aspergillosis within medical wards and intensive care units: a 4-year retrospective, observational, single-centre study. Internal and Emergency Medicine, 2021, 16, 1619-1627.	2.0	10
34	Infective Endocarditis in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology, 2021, 77, 1629-1640.	2.8	23
35	Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical Drug Investigation, 2021, 41, 539-548.	2.2	3
36	Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective. Frontiers in Medicine, 2021, 8, 617378.	2.6	11

#	Article	IF	CITATIONS
37	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. Open Forum Infectious Diseases, 2021, 8, ofab278.	0.9	31
38	Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. Pharmaceuticals, 2021, 14, 460.	3.8	2
39	Realâ€life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVIDâ€19 pneumonia. British Journal of Clinical Pharmacology, 2021, 87, 4861-4867.	2.4	7
40	Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Review of Respiratory Medicine, 2021, 15, 985-992.	2.5	4
41	Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. Diagnostics, $2021,11,869.$	2.6	1
42	Infections in SÃ@zary syndrome: A retrospective cohort study of 113 patients. Journal of the American Academy of Dermatology, $2021, , .$	1.2	2
43	Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry. Journal of Clinical Medicine, 2021, 10, 1951.	2.4	17
44	Oral neomycin and bacitracin are effective in preventing surgical site infections in elective colorectal surgery: a multicentre, randomized, parallel, single-blinded trial (COLORAL-1). Updates in Surgery, 2021, 73, 1775-1786.	2.0	6
45	Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury. Respiratory Physiology and Neurobiology, 2021, 288, 103645.	1.6	23
46	Matters of time. Intensive Care Medicine, 2021, 47, 1175-1176.	8.2	0
47	Poppies, Bloom. Journal of Medical Humanities, 2021, 42, 507-510.	0.7	0
48	Antibiotic De-escalation Experience in the Setting of Emergency Department: A Retrospective, Observational Study. Journal of Clinical Medicine, 2021, 10, 3285.	2.4	4
49	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2021, 10, 1837-1885.	4.0	28
50	Rationale for Polyclonal Intravenous Immunoglobulin Adjunctive Therapy in COVID-19 Patients: Report of a Structured Multidisciplinary Consensus. Journal of Clinical Medicine, 2021, 10, 3500.	2.4	4
51	Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study. BMC Infectious Diseases, 2021, 21, 806.	2.9	11
52	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. Biomedicines, 2021, 9, 1288.	3.2	6
53	Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?. International Immunopharmacology, 2021, 101, 108200.	3.8	20
54	Neurological comorbidities and COVID-19-related case fatality: A cohort study. Journal of the Neurological Sciences, 2021, 428, 117610.	0.6	8

#	Article	IF	Citations
55	Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements. Annals of Intensive Care, 2021, 11, 136.	4.6	31
56	Development of a Risk Prediction Model for Carbapenem-resistant <i>Enterobacteriaceae</i> Infection After Liver Transplantation: A Multinational Cohort Study. Clinical Infectious Diseases, 2021, 73, e955-e966.	5.8	22
57	Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study. Therapie, 2021, 76, 409-414.	1.0	2
58	Infection Control in the Era of COVID-19: A Narrative Review. Antibiotics, 2021, 10, 1244.	3.7	15
59	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. Separations, 2021, 8, 189.	2.4	5
60	Stuck in my head as an old song. European Journal of Internal Medicine, 2021, 94, 93-94.	2.2	0
61	Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection in Solid Organ Transplant Recipients: A Single-Center, Retrospective Study. Microorganisms, 2021, 9, 2272.	3.6	8
62	Exogenous Fungal Endophthalmitis: Clues to Aspergillus Aetiology with a Pharmacological Perspective. Microorganisms, 2021, 9, 74.	3.6	9
63	Gram-Positive Infections. Hematologic Malignancies, 2021, , 155-160.	0.2	0
64	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	2.9	46
65	Serology for Borrelia spp. in Northwest Italy: A Climate-Matched 10-Year Trend. Life, 2021, 11, 1310.	2.4	1
66	Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience. Frontiers in Cellular and Infection Microbiology, 2021, 11, 805514.	3.9	7
67	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. Frontiers in Pharmacology, 2021, 12, 755184.	3.5	5
68	Use of colistin in adult patients: A cross-sectional study. Journal of Global Antimicrobial Resistance, 2020, 20, 43-49.	2.2	29
69	Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?. Journal of Global Antimicrobial Resistance, 2020, 20, 22-27.	2.2	7
70	Visceral leishmaniasis in a patient with active HBV/HDV co-infection. Journal of Infection and Public Health, 2020, 13, 306-308.	4.1	3
71	The issue of the antifungal drug choice in prophylaxis of invasive fungal infection after liver transplant. Transplant Infectious Disease, 2020, 22, e13220.	1.7	1
72	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study., 2020, 2, e0220.		2

#	Article	IF	CITATIONS
73	Antecedent Administration of Angiotensinâ€Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVIDâ€19 Syndrome. Journal of the American Heart Association, 2020, 9, e017364.	3.7	29
74	Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. American Journal of Cardiology, 2020, 137, 111-117.	1.6	18
75	New cephalosporins for the treatment of pneumonia in internal medicine wards. Journal of Thoracic Disease, 2020, 12, 3747-3763.	1.4	14
76	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case–Control Study. Open Forum Infectious Diseases, 2020, 7, ofaa233.	0.9	7
77	COVID-19: in the uncertainty, do not try this at home. Internal and Emergency Medicine, 2020, 15, 1599-1600.	2.0	2
78	Fulminant septic shock due to Edwardsiella tarda infection associated with multiple liver abscesses: a case report and review of theÂliterature. Journal of Medical Case Reports, 2020, 14, 144.	0.8	8
79	CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins. Therapeutic Advances in Hematology, 2020, 11, 204062072097565.	2.5	8
80	The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock. Hemato, 2020, 1, 60-76.	0.6	3
81	Carbapenem-resistant Klebsiella pneumoniae in ICU-admitted COVID-19 patients: Keep an eye on the ball. Journal of Global Antimicrobial Resistance, 2020, 23, 398-400.	2.2	44
82	COVID ‶9: where have the lymphocytes gone?. Internal Medicine Journal, 2020, 50, 1436-1437.	0.8	2
83	COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?. Heart, 2020, 106, 1127-1131.	2.9	172
84	Outcome of COVIDâ€19 in liver transplant recipients: A preliminary report from Northwestern Italy. Transplant Infectious Disease, 2020, 22, e13353.	1.7	27
85	2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. Journal of Global Antimicrobial Resistance, 2020, 21, 22-27.	2.2	232
86	Insidious postoperative Aspergillus niger graft aortitis. IDCases, 2020, 21, e00823.	0.9	2
87	Beware of the dog. European Journal of Internal Medicine, 2020, 74, 102-103.	2.2	0
88	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. Antibiotics, 2020, 9, 71.	3.7	68
89	Point prevalence data on antimicrobial usage in Italian acute-care hospitals: Evaluation and comparison of results from two national surveys (2011–2016). Infection Control and Hospital Epidemiology, 2020, 41, 579-584.	1.8	11
90	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clinical Microbiology and Infection, 2020, 26, 880-894.	6.0	36

#	Article	IF	Citations
91	Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. Journal of Infection, 2020, 81, 131-146.	3.3	62
92	The management of anti-infective agents in intensive care units: the potential role of a  fast' pharmacology. Expert Review of Clinical Pharmacology, 2020, 13, 355-366.	3.1	14
93	Impact of imipenem concentration in lung perfusate and tissue biopsy during clinical ex-vivo lung perfusion of high-risk lung donors. Minerva Anestesiologica, 2020, 86, 617-626.	1.0	1
94	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase–producing <i>K. pneumoniae</i> . Clinical Infectious Diseases, 2019, 68, 355-364.	5.8	265
95	An unusual calf lesion in an immunocompromised patient. Internal and Emergency Medicine, 2019, 14, 441-445.	2.0	1
96	Surgical antimicrobial prophylaxis prescribing practices and impact on infection risk: Results from a multicenter surveillance study in Italy (2012-2017). American Journal of Infection Control, 2019, 47, 1426-1430.	2.3	10
97	Choosing wisely: what is the actual role of antimicrobial stewardship in Intensive Care Units?. Minerva Anestesiologica, 2019, 85, 71-82.	1.0	6
98	Real-life use of isavuconazole outside the hematological wards. European Journal of Internal Medicine, 2019, 70, e10-e12.	2.2	1
99	Enteropathogenetic nosocomial infections: predisposing clinical characteristics and risk of recurrent infections. Journal of Chemotherapy, 2019, 31, 394-400.	1.5	4
100	Ceftobiprole: drug evaluation and place in therapy. Expert Review of Anti-Infective Therapy, 2019, 17, 689-698.	4.4	42
101	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	3.3	67
102	V348I mutation in UL23 gene of human herpesvirus 1 in a case of herpetic hepatitis and haemophagocytic lymphohistiocytosis. New Microbes and New Infections, 2019, 29, 100529.	1.6	1
103	Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opinion on Pharmacotherapy, 2019, 20, 751-772.	1.8	8
104	Skin and soft tissue infections after breast surgery. Current Opinion in Infectious Diseases, 2019, 32, 87-94.	3.1	4
105	Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. Current Opinion in Infectious Diseases, 2019, 32, 663-673.	3.1	40
106	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp> gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project. Mycoses, 2019, 62, 310-319.	4.0	53
107	A Position Paper on IgM-Enriched Intravenous Immunoglobulin Adjunctive Therapy in Severe Acute Bacterial Infections: The TO-PIRO SCORE Proposal. New Microbiologica, 2019, 42, 176-180.	0.1	3
108	Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata. Infezioni in Medicina, 2019, 27, 328-331.	1.1	1

#	Article	IF	CITATIONS
109	Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 307-320.	4.4	100
110	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. Bone Marrow Transplantation, 2018, 53, 1304-1310.	2.4	12
111	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. Journal of Chemotherapy, 2018, 30, 157-171.	1.5	0
112	A simplified regimen of targeted antifungal prophylaxis in liver transplant recipients: A singleâ€center experience. Transplant Infectious Disease, 2018, 20, e12859.	1.7	17
113	The optimal duration of treatment for skin and soft tissue infections and acute bacterial skin and skin structure infections. Current Opinion in Infectious Diseases, 2018, 31, 155-162.	3.1	10
114	Neurological disease may precede lymphadenopathies in Actinomyces europaeus infection. Journal of Infection and Public Health, 2018, 11, 592-593.	4.1	3
115	Mortality and timing of surgery in the left-sided infective endocarditis: an Italian multicentre study. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 602-609.	1.1	7
116	Response to: â€~Letter to the Editor: "Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the artâ€â€™. Expert Review of Anti-Infective Therapy, 2018, 16, 369-371.	4.4	1
117	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	2.5	55
118	Management of KPC-producing Klebsiella pneumoniae infections. Clinical Microbiology and Infection, 2018, 24, 133-144.	6.0	136
119	Epidemiology and risk factors for mortality in bloodstream infection by CP-Kp, ESBL-E, Candida and CDI: A single center retrospective study. European Journal of Internal Medicine, 2018, 48, 44-49.	2.2	14
120	First case of E. meningoseptica in Italy in a patient with necrotic hemorrhagic pancreatitis. Infection, 2018, 46, 123-125.	4.7	5
121	2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World Journal of Emergency Surgery, 2018, 13, 58.	5.0	154
122	The GISA call to action for the appropriate use of antimicrobials and the control of antimicrobial resistance in Italy. International Journal of Antimicrobial Agents, 2018, 52, 127-134.	2.5	22
123	A retrospective study of viral central nervous system infections: relationship amongst aetiology, clinical course and outcome. Infection, 2017, 45, 227-231.	4.7	19
124	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
125	Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. International Journal of Antimicrobial Agents, 2017, 49, 784-785.	2.5	6
126	Minimal access surgery for mitral valve endocarditis. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 241-245.	1,1	7

#	Article	IF	Citations
127	Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients. Expert Review of Hematology, 2017, 10, 543-550.	2.2	14
128	Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 663-669.	2.9	32
129	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	1.6	34
130	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. Journal of Chemotherapy, 2017, 29, 197-214.	1.5	81
131	Liver transplantation with an uncommon full right hemiliver graft after hydatid cysts resection: Case report and review of the literature. Transplant Infectious Disease, 2017, 19, e12685.	1.7	1
132	Untargeted Antifungal Treatment Strategies for Invasive Candidiasis in Non-neutropenic Critically III Patients: Current Evidence and Insights. Current Fungal Infection Reports, 2017, 11, 84-91.	2.6	8
133	Management of multidrug-resistant <i>Pseudomonas aeruginosa</i> in the intensive care unit: state of the art. Expert Review of Anti-Infective Therapy, 2017, 15, 861-871.	4.4	51
134	Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients: TableÂ1 Journal of Antimicrobial Chemotherapy, 2017, 72, 319-321.	3.0	8
135	Antifungal Treatment Strategies in the ICU: Beyond Meta-analysis. Turkish Journal of Anaesthesiology and Reanimation, 2017, 44, 283-284.	0.8	4
136	Appropriate Treatment of Invasive Candidiasis in ICU: Timing, Colonization Index, Candida Score & Biomarkers, Towards de-Escalation?. Turkish Journal of Anaesthesiology and Reanimation, 2017, 44, 279-282.	0.8	10
137	Pharmacogenomic influence on sepsis outcome in critically ill patients. Infezioni in Medicina, 2017, 25, 45-49.	1.1	4
138	Management of carbapenem-resistant K. pneumoniae in allogenic stem cell transplant recipients: the Turin bundle. New Microbiologica, 2017, 40, 143-145.	0.1	6
139	Miliary pulmonary infection after BCG intravesical instillation: a rare, misdiagnosed and mistreated complication. Infezioni in Medicina, 2017, 25, 366-370.	1.1	4
140	The Gastrointestinal Microbiome and the Enteropathogenetic Syndromes. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
141	Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clinical Microbiology and Infection, 2016, 22, S27-S36.	6.0	122
142	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. European Journal of Internal Medicine, 2016, 34, 45-53.	2.2	8
143	Candidemia in Patients with Body Temperature Below 37°C and Admitted to Internal Medicine Wards: Assessment of Risk Factors. American Journal of Medicine, 2016, 129, 1330.e1-1330.e6.	1.5	16
144	Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically III Patients. Drugs, 2016, 76, 1161-1174.	10.9	29

#	Article	IF	Citations
145	Risk factors for mortality in patients with <i>Staphylococcus aureus </i> Journal of Chemotherapy, 2016, 28, 187-190.	1.5	10
146	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	3.0	129
147	Intrathecal or intraventricular colistin: a review. Infezioni in Medicina, 2016, 24, 3-11.	1.1	19
148	Multidrug-resistant bacteria and bloodstream infections in onco-hematological patients. Journal of Chemotherapy, 2015, 27, 250-252.	1.5	1
149	Current Pharmacological Treatment of Pulmonary Aspergillosis. Clinical Pulmonary Medicine, 2015, 22, 205-214.	0.3	O
150	The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards. PLoS ONE, 2015, 10, e0125149.	2.5	34
151	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 307-308.	3.0	10
152	From ESKAPE to ESCAPE, From KPC to CCC. Clinical Infectious Diseases, 2015, 60, 1289-1290.	5.8	36
153	Candida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 2365-2373.	3.2	68
154	One-year outcome following biological or mechanical valve replacement for infective endocarditis. International Journal of Cardiology, 2015, 178, 117-123.	1.7	24
155	Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Medicine, 2015, 41, 366-368.	8.2	13
156	Start Smart With Antimicrobial Stewardship: Table 1 Clinical Infectious Diseases, 2015, 61, 1033-1034.	5.8	3
157	Clinical epidemiology in Italian Registry of Infective Endocarditis (RIEI): Focus on age, intravascular devices and enterococci. International Journal of Cardiology, 2015, 190, 151-156.	1.7	41
158	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	3.0	434
159	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 2417-2418.	3.0	12
160	Critical issues for <i>Klebsiella pneumoniae</i> kPC-carbapenemase producing <i>K. pneumoniae</i> infections: a critical agenda. Future Microbiology, 2015, 10, 283-294.	2.0	39
161	Epidemiology and Treatment of MDR Enterobacteriaceae. Current Treatment Options in Infectious Diseases, 2015, 7, 291-316.	1.9	13
162	Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study. Clinical Microbiology and Infection, 2015, 21, 1106.e1-1106.e8.	6.0	148

#	Article	IF	CITATIONS
163	Infections caused by KPC-producing (i>Klebsiella pneumoniae (i>: differences in therapy and mortality in a multicentre studyâ€"authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 2922-2922.	3.0	60
164	Pharmacokinetics of high dosage of linezolid in two morbidly obese patientsâ€"authors' response: Figure 1 Journal of Antimicrobial Chemotherapy, 2015, 70, 3169-3169.	3.0	0
165	A one-year survey of carbapenemase-producing Klebsiella pneumoniae in Italy: beyond the ICU. Clinical Microbiology and Infection, 2015, 21, e11-e13.	6.0	17
166	Association Between Surgical Indications, Operative Risk, and Clinical Outcome in Infective Endocarditis. Circulation, 2015, 131, 131-140.	1.6	211
167	Impact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditis–Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, 741-749.	5 . 8	84
168	Current and future therapies for invasive aspergillosis. Pulmonary Pharmacology and Therapeutics, 2015, 32, 155-165.	2.6	16
169	Molecular Characterization of Toxigenic Clostridium difficile in a Northern Italian Hospital. Current Microbiology, 2015, 70, 154-155.	2.2	5
170	Candidemia, and infections by Clostridium difficile and carbapenemase-producing Enterobacteriaceae: new enteropathogenetic opportunistic syndromes?. Infezioni in Medicina, 2015, 23, 105-16.	1.1	14
171	Wound botulism after traumatic open fracture in Italy. Infezioni in Medicina, 2015, 23, 280-2.	1.1	1
172	A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. Infezioni in Medicina, 2015, 23, 367-9.	1.1	3
173	A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?. Current Drug Metabolism, 2014, 15, 581-598.	1.2	52
174	Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clinical Microbiology and Infection, 2014, 20, 1357-1362.	6.0	182
175	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug–drug interaction. Pharmacogenomics, 2014, 15, 1281-1286.	1.3	9
176	Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. Journal of Chemotherapy, 2014, 26, 315-320.	1.5	6
177	Combination of conventional blood cultures and the SeptiFast molecular test in patients with suspected sepsis for the identification of bloodstream pathogens. Diagnostic Microbiology and Infectious Disease, 2014, 79, 287-292.	1.8	24
178	Healthcare-Associated Klebsiella pneumoniae carbapenemase Producing K. pneumoniae Bloodstream Infection: The Time Has Come. Clinical Infectious Diseases, 2014, 59, 321-322.	5.8	8
179	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	2.5	48
180	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	5.8	843

#	Article	IF	Citations
181	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	3.2	7 5
182	Molecular epidemiology of methicillin-resistant S. aureus in the ICU setting. Intensive Care Medicine, 2014, 40, 759-760.	8.2	3
183	Amikacin dosing in the ICU: we now know more, but still not enough…. Intensive Care Medicine, 2014, 40, 1033-1035.	8.2	3
184	Development and validation of an UPLC–PDA method to quantify daptomycin in human plasma and in dried plasma spots. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 66-70.	2.8	37
185	Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome. BMC Anesthesiology, 2014, 14, 37.	1.8	27
186	Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review. Infection, 2014, 42, 801-809.	4.7	39
187	Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. Infezioni in Medicina, 2014, 22, 107-11.	1.1	3
188	High rate of respiratory MDR gram-negative bacteria in H1N1-ARDS treated with ECMO. Intensive Care Medicine, 2013, 39, $1880-1881$.	8.2	7
189	The Diagnostic Utility of Transthoracic Echocardiography for the Diagnosis of Infective Endocarditis in the Real World of the Italian Registry on Infective Endocarditis. Echocardiography, 2013, 30, 871-879.	0.9	8
190	Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. Clinical Infectious Diseases, 2013, 56, 1677-1678.	5.8	2
191	Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infectious Diseases, 2013, 13, 563.	2.9	39
192	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine, 2013, 39, 2092-2106.	8.2	169
193	Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. Scandinavian Journal of Infectious Diseases, 2013, 45, 882-884.	1.5	1
194	Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. International Journal of Antimicrobial Agents, 2013, 41, 590-591.	2.5	43
195	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 936, 42-47.	2.3	33
196	HACEK Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort. PLoS ONE, 2013, 8, e63181.	2.5	148
197	Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. Therapeutic Drug Monitoring, 2013, 35, 853-858.	2.0	16
198	Mortality in patients with early- or late-onset candidaemia. Journal of Antimicrobial Chemotherapy, 2013, 68, 927-935.	3.0	37

#	ARTICLE A(<scp>H</scp> 1 <scp>N</scp> 1)pdm09 hemagglutinin <scp>D</scp> 222 <scp>G</scp> and	IF	CITATIONS
199	\(\scp\)	3.4	20
200	Kinetics and prediction of <scp>HB</scp> sAg loss during therapy with analogues in patients affected by chronic hepatitis B <scp>HB</scp> eAg negative and genotype D. Liver International, 2013, 33, 580-585.	3.9	40
201	Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. Journal of Chemotherapy, 2013, 25, 376-378.	1.5	11
202	Reply to "ldentifying Patients Harboring Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae on Hospital Admission Is Not That Simple― Antimicrobial Agents and Chemotherapy, 2012, 56, 2220-2220.	3.2	1
203	Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population. Therapeutic Drug Monitoring, 2012, 34, 604-606.	2.0	6
204	Voriconazole in clinical practice. Journal of Chemotherapy, 2012, 24, 311-327.	1.5	49
205	Anidulafungin for Candida glabrata Infective Endocarditis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4552-4553.	3.2	18
206	Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. Journal of Antimicrobial Chemotherapy, 2012, 67, 2645-2649.	3.0	39
207	Three methods for estimating days of hospitalization because of hospitalâ€acquired infection: a comparison. Journal of Evaluation in Clinical Practice, 2012, 18, 776-780.	1.8	3
208	Blood stream infections after allogeneic stem cell transplantation: a singleâ€center experience with the use of levofloxacin prophylaxis. Transplant Infectious Disease, 2012, 14, 40-48.	1.7	49
209	The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis. Infection, 2012, 40, 77-80.	4.7	15
210	Ceftriaxone bone penetration in patients with septic non-union of the tibia. International Journal of Infectious Diseases, 2011, 15, e415-e421.	3.3	26
211	Anidulafungin treatment in a kidney transplant recipient with hepatic damage. Mycoses, 2011, 54, 12-15.	4.0	5
212	The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection, 2011, 39, 555-561.	4.7	37
213	Identifying Patients Harboring Extended-Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System. Antimicrobial Agents and Chemotherapy, 2011, 55, 3485-3490.	3.2	137
214	Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. Journal of Antimicrobial Chemotherapy, 2011, 66, 224-225.	3.0	19
215	Low Dosage Liposomal Amphotericin B in the Treatment of CandidaInfections in Critically III Patients. Journal of Chemotherapy, 2011, 23, 242-242.	1.5	1
216	Candidemia after cardiac surgery in the intensive care unit: an observational study. Interactive Cardiovascular and Thoracic Surgery, 2011, 12, 374-378.	1.1	20

#	Article	lF	Citations
217	Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia. Journal of Chemotherapy, 2010, 22, 397-401.	1.5	3
218	Medical therapy of pericardial diseases. Journal of Cardiovascular Medicine, 2010, 11, 712-722.	1.5	106
219	The prophylaxis of infective endocarditis: a joint position study of the Italian Federation of Cardiologists and the Italian Society of Infectious and Tropical Diseases. Journal of Cardiovascular Medicine, 2010, 11, 419-425.	1.5	5
220	Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Analytical and Bioanalytical Chemistry, 2010, 396, 791-798.	3.7	68
221	Detection of WAB cells in hepatitis C virus infection: A potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis and Rheumatism, 2010, 62, 2152-2159.	6.7	37
222	Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses, 2010, 53, 275-278.	4.0	25
223	Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma. Antimicrobial Agents and Chemotherapy, 2010, 54, 3408-3413.	3.2	51
224	Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. International Journal of Infectious Diseases, 2010, 14, S79-S92.	3.3	102
225	Early Experience with Highâ€Dosage Daptomycin for Prosthetic Infections. Clinical Infectious Diseases, 2009, 49, 1772-1773.	5.8	8
226	Prevention and Diagnosis of Ventilator-Associated Pneumonia. Chest, 2009, 135, 881-882.	0.8	3
227	Observations on Cryoglobulin Testing: II. The Association of Oligoclonal Mixed Cryoglobulinemia with Cirrhosis in Patients Infected with Hepatitis C Virus: Table 1 Journal of Rheumatology, 2009, 36, 1956-1957.	2.0	6
228	Efficacy of Early Pegylated Interferon αâ€2b Monotherapy for Acute Hepatitis C in HIVâ€Infected Patients. Clinical Infectious Diseases, 2009, 48, 1636-1637.	5.8	2
229	Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report. Intensive Care Medicine, 2009, 35, 1641-1643.	8.2	8
230	Aetiological diagnosis in acute and recurrent pericarditis: when and how. Journal of Cardiovascular Medicine, 2009, 10, 217-230.	1.5	85
231	Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV. Therapeutic Drug Monitoring, 2009, 31, 104-109.	2.0	42
232	Observations on Cryoglobulin Testing: I. The Association of Cryoglobulins Containing Rheumatoid Factors with Manifestation of Cryoglobulinemic Vasculitis. Journal of Rheumatology, 2009, 36, 1953-1955.	2.0	21
233	Cryoglobulinemia-Related Vasculitis During Effective Anti-HCV Treatment with PEG-Interferon alfa-2b. Infection, 2008, 36, 285-287.	4.7	7
234	Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia. Clinical Pharmacokinetics, 2008, 47, 793-805.	3.5	36

#	Article	IF	CITATIONS
235	Post-Traumatic Osteomyelitis Due toAspergillus flavusSuccessfully Treated with Voriconazole: A Case Report. Journal of Chemotherapy, 2008, 20, 524-526.	1.5	7
236	Infective endocarditis in the real world: the Italian Registry of Infective Endocarditis (Registro) Tj ETQq0 0 0 rgBT	Oyerlock :	10 Tf 50 702
237	A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting. Therapeutic Drug Monitoring, 2008, 30, 90-94.	2.0	12
238	Twelve-Week Treatment of Acute Hepatitis C Virus with Pegylated Interferon-Â-2b in Injection Drug Users. Clinical Infectious Diseases, 2007, 45, 583-588.	5.8	37
239	Non-HACEK Gram-Negative Bacillus Endocarditis. Annals of Internal Medicine, 2007, 147, 829.	3.9	229
240	Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. Journal of Antimicrobial Chemotherapy, 2007, 59, 565-568.	3.0	11
241	Infective endocarditis in drug addicts: role of HIV infection and the diagnostic accuracy of Duke criteria. Journal of Cardiovascular Medicine, 2007, 8, 169-175.	1.5	19
242	Haematological safety of long-term therapy with linezolid. International Journal of Antimicrobial Agents, 2007, 29, 480-483.	2.5	10
243	A short course of pegylated interferon-? in acute HCV hepatitis. Journal of Viral Hepatitis, 2007, 14, 116-121.	2.0	62
244	Infective Endocarditis in Intravenous Drug Users from Italy: the Increasing Importance in HIV-infected Patients. Infection, 2007, 35, 154-160.	4.7	32
245	Continuous infusion of amphotericin B deoxycholate: Does decreased nephrotoxicity couple with time-dependent pharmacodynamics?. Leukemia and Lymphoma, 2006, 47, 1964-1966.	1.3	7
246	Resolution of HCV infection after highly active antiretroviral therapy in a HIV–HCV coinfected patient. Journal of Infection, 2006, 53, e215-e218.	3.3	16
247	Acute hepatitis C: Dosage and compliance. Hepatology, 2006, 44, 511-511.	7.3	2
248	Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. Journal of Antimicrobial Chemotherapy, 2006, 57, 360-363.	3.0	32
249	A Man with Chronic Leg Edema, Purpuric Skin Lesions, and Abdominal Lymphadenopathy. Clinical Infectious Diseases, 2005, 41, 519-520.	5.8	3
250	Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Primary Resistance Mutations in a Clinical Setting. Antimicrobial Agents and Chemotherapy, 2005, 49, 3966-3969.	3.2	65
251	Osteomyelitis Caused by Enterobacter cancerogenus Infection following a Traumatic Injury: Case Report and Review of the Literature. Journal of Clinical Microbiology, 2005, 43, 1459-1461.	3.9	32
252	Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. Journal of Antimicrobial Chemotherapy, 2005, 55, 280-281.	3.0	36

#	Article	IF	Citations
253	Treatment of Acute C Hepatitis in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 110-111.	2.1	2
254	Treatment of acute C hepatitis in intravenous drug users. Journal of Hepatology, 2005, 43, 186-187.	3.7	5
255	Extrahepatic disease manifestations of HCV infection: some current issues. Journal of Hepatology, 2004, 40, 341-352.	3.7	132
256	Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. Aids, 2004, 18, 577-578.	2.2	7
257	Invasive Pulmonary Aspergillosis Soon After Therapy With Infliximab, a Tumor Necrosis Factor-Alpha–Neutralizing Antibody: A Possible Healthcare-Associated Case?. Infection Control and Hospital Epidemiology, 2003, 24, 477-482.	1.8	98
258	Treatment of Latent Tuberculosis Infection. New England Journal of Medicine, 2003, 348, 1292-1293.	27.0	9
259	Healthy Ranges for Alanine Aminotransferase Levels. Annals of Internal Medicine, 2003, 138, 156.	3.9	4
260	Tuberculosis and Treatment with Infliximab. New England Journal of Medicine, 2002, 346, 623-626.	27.0	140
261	Nosocomial pneumonia: emerging concepts in diagnosis, management, and prophylaxis. Current Opinion in Critical Care, 2002, 8, 421-429.	3.2	35
262	Influence of age and autoimmunity on liver disease in HCV-associated type II mixed cryoglobulinemia. Human Immunology, 2002, 63, 751-757.	2.4	12
263	Anti-neutrophil cytoplasmic antibodies in echinococcus granulosus hydatid disease. Human Immunology, 2001, 62, 1122-1126.	2.4	7
264	Neurocysticercosis: an unusual presentation of a rare disease. Journal of Neurology, 2001, 248, 139-140.	3.6	5
265	Infective Endocarditis in Patients with Human Immunodeficiency Virus Infection. Journal of Infection, 2001, 42, 267-271.	3.3	54
266	Letters to the Editor. Journal of Hepatology, 2000, 33, 1027-1028.	3.7	0
267	Mixed cryoglobulinemia secondary to visceral Leishmaniasis. Arthritis and Rheumatism, 1999, 42, 2007-2011.	6.7	33
268	HCV/HGV coinfection and cryoglobulinemia. Journal of Hepatology, 1998, 28, 355-356.	3.7	5
269	Antineutrophil cytoplasmic antibodies in autoimmune thyroid disorders. Endocrine Research, 1998, 24, 185-194.	1.2	19
270	Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate. Inflammopharmacology, 1997, 5, 153-158.	3.9	21

#	Article	IF	CITATIONS
271	Expression of lactoferrin on human granulocytes: analysis with polyclonal and monoclonal antibodies. Clinical and Experimental Immunology, 1997, 109, 279-285.	2.6	34